Citation

Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN.: Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem, Volume 51 (5), 2008

Authors

Biller SA, Deshpande PP, Discenza L, Ellsworth BA, Flint OP, Girotra RN, Hagan DL, Han S, Humphreys WG, Janovitz EB, Khanna A, McCann PJ, Meng W, Morgan N, Morrison EP, Nirschl AA, Obermeier MT, Patel M, Pullockaran A, Robertson JG, Sher PM, Taylor JR, Wang A, Washburn WN., Wetterau JR, Whaley JM, Wu G, Zahler R

Journal

J Med Chem

Year

2008

DOI

10.1021/jm701272q

PubMed

18260618

Machine-readable

REST APIRDF